Overview

Efalizumab in the Treatment of Alopecia, Phase II

Status:
Withdrawn

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

Determine the effect that treatment with efalizumab has on scalp hair re-growth in younger adults affected by severe variants of alopecia areata, including alopecia totalis, alopecia universalis, and severe ophiasis variants.

Phase:

Phase 2

Details

Lead Sponsor:

Northwestern University

Collaborator:

Genentech, Inc.

Treatments:

Antibodies, Monoclonal